Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel DiseasesKate D. Lynch, Cynthia Levy, Roger W. Chapman et al.|Clinical Gastroenterology and Hepatology|2019Cited by 104
Alkaline Phosphatase Changes With Seladelpar Across Subgroups Of Primary Biliary Cholangitis Patients In The Response TrialKris Kowdley, Charles A. McWherter, Franco Frigerio et al.|Digestive and Liver Disease|2025Cited by 2
P0897 : Efficacy of simeprevir and sofosbuvir for treatment of cirrhotic patients with genotype 1 chronic hepatitis C – a single center experienceVirendra Singh, Stewart Cooper, Thorburn Frederick et al.|Journal of Hepatology|2015Cited by 1
Alkaline phosphatase changes with seladelpar across subgroups of primary biliary cholangitis patients in the response trialKris V. Kowdley, Charles A. McWherter, Kidist Yimam et al.|Zeitschrift für Gastroenterologie|2025Cited by 0